Importantly, anti-AGR2 and anti-IGFBP5 levels were significantly higher in the malignant CMT group compared with the benign CMT group (Figure 3), suggesting their potential as serum biomarkers for CMT malignancy. The gene discussed is IGFBP5; the disease is Charcot-Marie-Tooth disease.